Table 3 Adverse Events in Pazopanib Recipients by Number of Prior Lines of Therapy (Safety Population)
Events, n (%) | 1 prior line (n = 109) | 2+ prior lines (n = 131) |
|---|---|---|
Any on-therapy AE | 108 (> 99) | 129 (98) |
AEs related to study treatment | 101 (93) | 118 (90) |
AEs leading to permanent discontinuation or early withdrawal | 24 (22) | 24 (18) |
AEs leading to dose reduction | 38 (35) | 39 (30) |
AEs leading to dose interruption/delay | 59 (54) | 61 (47) |
Any SAE | 47 (43) | 52 (40) |
SAEs related to study treatment | 26 (24) | 31 (24) |
Fatal SAEs | 5 (5) | 3 (2) |
Fatal SAEs related to study treatment | 0 (0) | 1 (< 1) |